Acc017
Preclinical
Acc017 is one of 3 therapeutic programs targeting Infection, Human Immunodeficiency Virus. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in Infection, Human Immunodeficiency Virus
#DrugCompanyPhaseTrials
1CAB LA
GSKPhase 3
ACC017+FTC/TAF
JJiangsu Aidea Pharmaceutical Group Co., Ltd.
Preclinical
Acc017
JJiangsu Aidea Pharmaceutical Group Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Infection, Human Immunodeficiency Virus1 trial
Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Active, not recruiting·JJiangsu Aidea Pharmaceutical Group Co., Ltd.·Preclinical·NCT07711210·12 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Acc017. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]